Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1

被引：0
|
作者：
Fasching, P. A. [1 ]
Huang, M. [2 ]
Haiderali, A. [3 ]
Pan, W. [4 ]
Hu, P. [2 ]
Chaudhuri, M. [5 ]
De Tilleghem, C. Le Bailly [6 ]
Cappoen, N. [6 ]
O'Shaughnessy, J. [7 ]
机构：
[1] Univ Hosp Erlangen, Dept Gynecol & Obstet, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
[2] Merck & Co Inc, Econ & Data Sci, MRL Labs, Upper Gwynedd Campus, N Wales, PA USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Corp Headquarters, Kenilworth, NJ USA
[4] Merck & Co Inc, Oncol Dept, Rahway, NJ 07065 USA
[5] CHEORS Complete Hlth Econ Outcomes & Res Solut, Oncol, N Wales, PA USA
[6] HTA Stat Europe MSD, Brussels, Belgium
[7] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol,US Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
159P
引用
收藏
页码：S192 / S193
页数：2
相关论文
共 50 条
  • [41] Advanced or metastatic Urothelial Carcinoma New First-line Strategy established with PD-L1 Inhibitor
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [42] PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1 negative metastatic lung adenocarcinoma: A real-world data
    Ge, Yihui
    Sun, Yuping
    Gao, Aiqin
    Li, Juan
    Wang, Dahai
    Wu, Jiake
    Sun, Yanxin
    Sun, Haifeng
    Sun, Haodong
    Li, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    CANCERS, 2020, 12 (12) : 1 - 15
  • [44] First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
    Thierry Landre
    Gaetan Des Guetz
    Kader Chouahnia
    Cherifa Taleb
    Alain Vergnenègre
    Christos Chouaïd
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 441 - 448
  • [45] First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
    Landre, Thierry
    Guetz, Gaetan Des
    Chouahnia, Kader
    Taleb, Cherifa
    Vergnenegre, Alain
    Chouaid, Christos
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 441 - 448
  • [46] An indirect Comparison of Pembrolizumab plus Chemo vs Ipilimumab plus Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S23
  • [47] Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma
    Zhao, Lu
    Zhang, Zhengfeng
    Wang, Dazhen
    Yang, Liu
    Liu, Ze
    Lou, Changjie
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [48] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
    Descourt, Renaud
    Chouaid, Christos
    Perol, Maurice
    Besse, Benjamin
    Greillier, Laurent
    Bylicki, Olivier
    Ricordel, Charles
    Guisier, Florian
    Gervais, Radj
    Schott, Roland
    Auliac, Jean-Bernard
    Robinet, Gilles
    Decroisette, Chantal
    FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016
  • [49] Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
    Piedra, A.
    Recio, S. Martinez
    Gonzalez, A. Hernandez
    Bueno, M. T. Moran
    Arriola, E.
    Recuero-Borau, J.
    Dols, M. Cobo
    Gonzalez, P. Cordeiro
    Martinez, J. Mosquera
    Garcia-Campelo, M. R.
    Blanco, A. Calles
    Alvarez, R. M.
    Garcia, M. Zapata
    Casado, M. D. Isla
    Perez, A. Callejo
    Gomez, P. Iranzo
    Joaquin, A. Barba
    Sullivan, I. G.
    Felip, E.
    Majem, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [50] Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS ≥ 10) metastatic and advanced triple-negative breast cancer
    Loison, Rebecca
    Loirat, Delphine
    BULLETIN DU CANCER, 2022, 109 (04) : 387 - 389
12345